Similarly, PT1001B (PRMT1 inhibitor) enhances antitumor immunity by inhibiting PD-L1 expression on tumor cells, upregulating tumor-infiltrating CD8+ T lymphocytes. This evidence concerns the gene CD8A and neoplasm.